Arginine-Gingipain B (RgpB) antibody

Catalog No. ABIN7489927

The Mouse Monoclonal anti-Arginine-Gingipain B (RgpB) antibody is suitable to detect Arginine-Gingipain B (RgpB) in samples from Porphyromonas gingivalis. It has been validated for IHC and WB.

Quick Overview for Arginine-Gingipain B (RgpB) antibody (ABIN7489927)

Target: Arginine-Gingipain B (RgpB)

Reactivity: Porphyromonas gingivalis

Host: Mouse

Clonality: Monoclonal

Application: Immunohistochemistry (IHC), Western Blotting (WB)

Clone: 18E6-F7

Product Details

Specificity: This antibody recognizes a unique epitope within the immunoglobulin (Ig)-like domain of arginine-gingipain (RgpB).

Cross-Reactivity: Porphyromonas gingivalis

Immunogen: Arginine-gingipain B (RgpB) from Porphyromonas gingivalis.

Isotype: IgG1

Application Details

Application Notes: Paraffin-embedded formalin-fixed AD hippocampus and gingival tissue from a patient with periodontal disease stained with #13925 and compared to non-AD control tissue and mouse IgG1 control (see Dominy et al. Science Advances 5 (1): eaau3333).
Detection of RgpB in P. gingivalis wild-type strain W83 whole cells (see Nguyen K-A et al. J Bacteriol 189: 833-843).

Comment:

Anti-Gngipaing B (RgpB) Mouse Monoclonal Antibody

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: Dilute in PBS or medium that is identical to that used in the assay system.

Concentration: Lot specific

Buffer: PBS, pH 7.4,Phosphate Buffered Saline

Storage: -20 °C

Storage Comment: This antibody is stable for at least one (1) year at -20°C. Store in appropriate aliquots to avoid multiple freeze-thaw cycles.

Target Details

Target: Arginine-Gingipain B (RgpB)

Background: Gingipain B,Arginine-gingipain B (RgpB) is a cysteine protease produced exclusively by Porphyromonas gingivalis, and it plays a central role in the pathogenicity of P. gingivalis in periodontal disease. Over the last several years, a possible association between Alzheimer disease (AD) and chronic periodontitis has been suggested based on detection of P. gingivalis infiltration in autopsy specimens from the brains of people with AD in association with neurons, tau tangles, and beta-amyloid as well as in cerebrospinal fluid of individuals diagnosed with AD. Oral administration of a gingipain inhibitor to mice with established brain infection by P. gingivalis decreased the amount of P. gingivalis DNA in brain as well as the levels of beta-amyloid and tumor necrosis factor-α. Taken together, the data suggest that gingipain inhibitors might be an effective treatment of AD. Clinical trials of gingipain inhibitors are currently underway.,Arginine-gingipain B

UniProt: Q51844